FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568800115> ?p ?o ?g. }

• W2568800115 endingPage "272" @default.
• W2568800115 startingPage "259" @default.
• W2568800115 abstract "In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment’s safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed. A prospective PV cohort was developed. Regulatory approval was obtained in Sudan, Kenya, Uganda and Ethiopia. Twelve sentinel sites sponsored by the Ministries of Health, Médecins Sans Frontières (MSF) and Drugs for Neglected Diseases initiative (DNDi) participated. VL patients treated using the new treatment were consented and included in a common registry that collected demographics, baseline clinical characteristics, adverse events, serious adverse events and treatment outcomes. Six-monthly periodic safety update reports (PSUR) were prepared and reviewed by a PV steering committee. Overall 3126 patients were enrolled: 1962 (62.7%) from Sudan, 652 (20.9%) from Kenya, 322 (10.3%) from Ethiopia and 190 (6.1%) from Uganda. Patients were mostly male children (68.1%, median age 11 years) with primary VL (97.8%). SSG-PM initial cure rate was 95.1%; no geographical differences were noted. HIV/VL co-infected patients and patients older than 50 years had initial cure rates of 56 and 81.4%, respectively, while 1063 (34%) patients had at least one adverse event (AE) during treatment and 1.92% (n = 60) had a serious adverse event (SAE) with a mortality of 1.0% (n = 32). There were no serious unexpected adverse drug reactions. This first regional PV programme in VL supports SSG-PM combination as first-line treatment for primary VL in Eastern Africa. SSG-PM was effective and safe except in HIV/VL co-infected or older patients. Active PV surveillance of targeted safety, effectiveness and key VL outcomes such us VL relapse, PKDL and HIV/VL co-infection should continue and PV data integrated to national and WHO PV databases." @default.
• W2568800115 created "2017-01-13" @default.
• W2568800115 creator A5000504924 @default.
• W2568800115 creator A5004027056 @default.
• W2568800115 creator A5005073543 @default.
• W2568800115 creator A5006896277 @default.
• W2568800115 creator A5008098933 @default.
• W2568800115 creator A5020609274 @default.
• W2568800115 creator A5021667508 @default.
• W2568800115 creator A5022301113 @default.
• W2568800115 creator A5022685524 @default.
• W2568800115 creator A5024500372 @default.
• W2568800115 creator A5027534520 @default.
• W2568800115 creator A5031353369 @default.
• W2568800115 creator A5031626110 @default.
• W2568800115 creator A5036492095 @default.
• W2568800115 creator A5039593201 @default.
• W2568800115 creator A5040323045 @default.
• W2568800115 creator A5041401888 @default.
• W2568800115 creator A5045460409 @default.
• W2568800115 creator A5056143866 @default.
• W2568800115 creator A5056783375 @default.
• W2568800115 creator A5063364805 @default.
• W2568800115 creator A5070984672 @default.
• W2568800115 creator A5072297458 @default.
• W2568800115 creator A5073032840 @default.
• W2568800115 creator A5080804875 @default.
• W2568800115 creator A5083165391 @default.
• W2568800115 date "2017-01-09" @default.
• W2568800115 modified "2023-10-16" @default.
• W2568800115 title "Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme" @default.
• W2568800115 cites W1170688339 @default.
• W2568800115 cites W1793853564 @default.
• W2568800115 cites W1894181283 @default.
• W2568800115 cites W1978949702 @default.
• W2568800115 cites W1982569695 @default.
• W2568800115 cites W1983294679 @default.
• W2568800115 cites W2025903791 @default.
• W2568800115 cites W2046144222 @default.
• W2568800115 cites W2056949124 @default.
• W2568800115 cites W2057676788 @default.
• W2568800115 cites W2062016511 @default.
• W2568800115 cites W2072809427 @default.
• W2568800115 cites W2074289946 @default.
• W2568800115 cites W2076026695 @default.
• W2568800115 cites W2079519145 @default.
• W2568800115 cites W2092837308 @default.
• W2568800115 cites W2100243294 @default.
• W2568800115 cites W2107915297 @default.
• W2568800115 cites W2108642691 @default.
• W2568800115 cites W2109788582 @default.
• W2568800115 cites W2115969254 @default.
• W2568800115 cites W2123082391 @default.
• W2568800115 cites W2128772170 @default.
• W2568800115 cites W2136086972 @default.
• W2568800115 cites W2144756920 @default.
• W2568800115 cites W2155283295 @default.
• W2568800115 cites W2158525972 @default.
• W2568800115 cites W2495593729 @default.
• W2568800115 cites W2519666645 @default.
• W2568800115 cites W4248396965 @default.
• W2568800115 cites W1912945808 @default.
• W2568800115 doi "https://doi.org/10.1007/s40261-016-0481-0" @default.
• W2568800115 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5315726" @default.
• W2568800115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28066878" @default.
• W2568800115 hasPublicationYear "2017" @default.
• W2568800115 type Work @default.
• W2568800115 sameAs 2568800115 @default.
• W2568800115 citedByCount "45" @default.
• W2568800115 countsByYear W25688001152017 @default.
• W2568800115 countsByYear W25688001152018 @default.
• W2568800115 countsByYear W25688001152019 @default.
• W2568800115 countsByYear W25688001152020 @default.
• W2568800115 countsByYear W25688001152021 @default.
• W2568800115 countsByYear W25688001152022 @default.
• W2568800115 countsByYear W25688001152023 @default.
• W2568800115 crossrefType "journal-article" @default.
• W2568800115 hasAuthorship W2568800115A5000504924 @default.
• W2568800115 hasAuthorship W2568800115A5004027056 @default.
• W2568800115 hasAuthorship W2568800115A5005073543 @default.
• W2568800115 hasAuthorship W2568800115A5006896277 @default.
• W2568800115 hasAuthorship W2568800115A5008098933 @default.
• W2568800115 hasAuthorship W2568800115A5020609274 @default.
• W2568800115 hasAuthorship W2568800115A5021667508 @default.
• W2568800115 hasAuthorship W2568800115A5022301113 @default.
• W2568800115 hasAuthorship W2568800115A5022685524 @default.
• W2568800115 hasAuthorship W2568800115A5024500372 @default.
• W2568800115 hasAuthorship W2568800115A5027534520 @default.
• W2568800115 hasAuthorship W2568800115A5031353369 @default.
• W2568800115 hasAuthorship W2568800115A5031626110 @default.
• W2568800115 hasAuthorship W2568800115A5036492095 @default.
• W2568800115 hasAuthorship W2568800115A5039593201 @default.
• W2568800115 hasAuthorship W2568800115A5040323045 @default.
• W2568800115 hasAuthorship W2568800115A5041401888 @default.
• W2568800115 hasAuthorship W2568800115A5045460409 @default.
• W2568800115 hasAuthorship W2568800115A5056143866 @default.
• W2568800115 hasAuthorship W2568800115A5056783375 @default.
• W2568800115 hasAuthorship W2568800115A5063364805 @default.

• next